Revolutionizing Bone Health with Osteoboost Wearable
March 10, 2024, 7:35 pm
Location: United States, California, San Francisco
Employees: 11-50
Founded date: 2018
Total raised: $7.5M
Bone Health Technologies (BHT) secures $5M funding for Osteoboost, a game-changing solution for osteopenia and osteoporosis.
Bone Health Technologies (BHT) is shaking up the bone health industry with its innovative Osteoboost wearable device. This cutting-edge technology, backed by $5 million in funding from top investment firms like Esplanade Ventures and Terumo Medical, is set to transform the way postmenopausal women manage bone density decline.
Osteoboost, a hip belt worn as a smart device, harnesses the power of precise vibrations to activate the body's natural bone regeneration process. Through clinical trials, Osteoboost has proven to significantly slow down bone density loss and boasts an impressive user adherence rate of over 80%.
With over 64 million Americans grappling with osteopenia and osteoporosis, Osteoboost emerges as a beacon of hope in a $30 billion market. BHT's focus on non-pharmacological solutions and FDA clearance positions Osteoboost as a game-changer in bone health management.
The technology behind Osteoboost is rooted in NASA research, which demonstrated the benefits of whole-body vibration for improving bone health. By localizing vibrations to the sacrum, Osteoboost offers a convenient and effective solution for individuals looking to prevent osteoporosis.
CEO Laura Yecies emphasizes the importance of clinical validation and FDA clearance in bringing Osteoboost to market. With a strong focus on efficacy and user safety, BHT is poised to revolutionize bone health for women worldwide.
Clinical trials have shown promising results, with participants experiencing a significant reduction in bone loss and preservation of bone strength. This is particularly crucial for women over 50, who face a high risk of fractures due to osteoporosis.
As BHT gears up for the public launch of Osteoboost later this year, the company aims to deliver a comprehensive solution for improving bone health and reducing fractures. With a focus on digital therapeutics and clinical services, Osteoboost represents a groundbreaking approach to addressing the widespread issue of low bone density.
In a market hungry for non-pharmacological treatments for osteopenia and osteoporosis, Osteoboost shines as a beacon of innovation and hope. With a strong foundation in science, technology, and clinical validation, BHT is on a mission to reshape the landscape of bone health for generations to come.
Bone Health Technologies (BHT) is shaking up the bone health industry with its innovative Osteoboost wearable device. This cutting-edge technology, backed by $5 million in funding from top investment firms like Esplanade Ventures and Terumo Medical, is set to transform the way postmenopausal women manage bone density decline.
Osteoboost, a hip belt worn as a smart device, harnesses the power of precise vibrations to activate the body's natural bone regeneration process. Through clinical trials, Osteoboost has proven to significantly slow down bone density loss and boasts an impressive user adherence rate of over 80%.
With over 64 million Americans grappling with osteopenia and osteoporosis, Osteoboost emerges as a beacon of hope in a $30 billion market. BHT's focus on non-pharmacological solutions and FDA clearance positions Osteoboost as a game-changer in bone health management.
The technology behind Osteoboost is rooted in NASA research, which demonstrated the benefits of whole-body vibration for improving bone health. By localizing vibrations to the sacrum, Osteoboost offers a convenient and effective solution for individuals looking to prevent osteoporosis.
CEO Laura Yecies emphasizes the importance of clinical validation and FDA clearance in bringing Osteoboost to market. With a strong focus on efficacy and user safety, BHT is poised to revolutionize bone health for women worldwide.
Clinical trials have shown promising results, with participants experiencing a significant reduction in bone loss and preservation of bone strength. This is particularly crucial for women over 50, who face a high risk of fractures due to osteoporosis.
As BHT gears up for the public launch of Osteoboost later this year, the company aims to deliver a comprehensive solution for improving bone health and reducing fractures. With a focus on digital therapeutics and clinical services, Osteoboost represents a groundbreaking approach to addressing the widespread issue of low bone density.
In a market hungry for non-pharmacological treatments for osteopenia and osteoporosis, Osteoboost shines as a beacon of innovation and hope. With a strong foundation in science, technology, and clinical validation, BHT is on a mission to reshape the landscape of bone health for generations to come.